Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

9921	Companies
200228	Keywords
131003	Articles
106378	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 02/25/2026 at 08:05, 3 hours 5 minutes ago

Pentixapharm fait progresser son programme d'hémato-oncologie basé sur le CXCR4 grâce à l'approbation de la FDA

Greffe De Cellules Souches Approbation De La FDA Radiothéranostique Hémato-oncologie Ciblage De CXCR4
BRIEF

published on 02/25/2026 at 08:05, 3 hours 5 minutes ago

Pentixapharm Advances CXCR4-Based Hemato-Oncology Program with FDA Approval

FDA Approval Hemato-oncology CXCR4-targeted Radiotheranostic Stem Cell Transplant
PRESS RELEASE

published on 02/25/2026 at 08:00, 3 hours 10 minutes ago

Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
Pentixapharm receives FDA approval for dual theranostic INDs in hemato-oncology program, targeting AML and MM with CXCR4-directed radiotherapy

FDA Approval Pentixapharm CXCR4 Dual Theranostic Hemato-oncology Program
BRIEF

published on 02/05/2026 at 08:35, 20 days 2 hours ago

Le PENTIXAFOR de Pentixapharm se révèle prometteur dans le diagnostic non invasif de l'hyperaldostéronisme primaire

Aldostéronisme Primaire Données De La Phase 2 PENTIXAFORME Diagnostic Non Invasif Imagerie PET/CT
BRIEF

published on 02/05/2026 at 08:35, 20 days 2 hours ago

Pentixapharm's PENTIXAFOR Shows Promise in Non-Invasive Diagnosis of Primary Aldosteronism

Primary Aldosteronism PentixaFor Phase 2 Data Non-invasive Diagnostic PET/CT Imaging
PRESS RELEASE

published on 02/05/2026 at 08:30, 20 days 2 hours ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
Pentixapharm announces Phase 2 study results supporting PENTIXAFOR as a superior non-invasive PET-diagnostic for Primary Aldosteronism, enhancing patient care in hypertension

Phase 2 Molecular Imaging Pentixapharm Primary Aldosteronism PET-diagnostic
BRIEF

published on 01/07/2026 at 08:05, 1 month 18 days ago

Pentixapharm reçoit des commentaires de la FDA concernant une étude sur l'hypertension

Hypertension Produits Radiopharmaceutiques Étude De Phase 3 Pentixapharm Commentaires De La FDA
BRIEF

published on 01/07/2026 at 08:05, 1 month 18 days ago

Pentixapharm Receives FDA Feedback for Hypertension Study

FDA Feedback Hypertension Radiopharmaceuticals Phase 3 Study Pentixapharm
PRESS RELEASE

published on 01/07/2026 at 08:00, 1 month 18 days ago

Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
Pentixapharm receives FDA feedback for Phase 3 diagnostic study in hypertension, providing clarity on study design and approval pathway. Formal guidance enhances IND submission preparations

FDA Feedback Diagnostic Hypertension Phase 3 Study Pentixapharm
BRIEF

published on 12/03/2025 at 08:05, 2 months 22 days ago

Pentixapharm se prépare à l'étude de phase 3 PANDA sur le diagnostic de l'hypertension

Hypertension Étude De Phase 3 Radiodiagnostic Commentaires De La FDA Ciblage De CXCR4

Accesswire

Published on 02/25/2026 at 11:00, 10 minutes ago

Grande Portage Resources Secures Drilling Contractor for 2026 Program at the New Amalga Gold Project and Provides Project Update
Published on 02/25/2026 at 09:01, 2 hours 9 minutes ago

Noram Adds Additional Critical Mineral to List of High-Value Byproduct Credits in Zeus Project Upgraded PEA
Published on 02/25/2026 at 08:05, 3 hours 5 minutes ago

Tocvan Builds Momentum at Gran Pilar: Six Exploration Holes Drilled, Drone Mag Survey and Water Monitoring Wells for Pilot Completed
Published on 02/25/2026 at 08:00, 3 hours 10 minutes ago

Touchstone Exploration Announces 2025 Year-End Reserves
Published on 02/25/2026 at 01:10, 10 hours ago

Northfield Announces Intention to Commence Normal Course Issuer Bid

View all ACCESSWIRE

EQS Group

Published on 02/25/2026 at 11:00, 9 minutes ago

EQS-Adhoc: IVU Traffic Technologies AG: Preliminary financial figures 2025 – IVU again on record course – special dividend proposed
Published on 02/25/2026 at 10:25, 45 minutes ago

SINEXCEL Recognized as BloombergNEF Tier 1 Power Inverter Manufacturer for Q1 2026
Published on 02/25/2026 at 10:05, 1 hour 5 minutes ago

Datamaran Launches Regulatory Monitoring Solution to Help Companies Navigate ESG Complexity
Published on 02/25/2026 at 10:05, 1 hour 5 minutes ago

2026: Transparency Becomes a New Standard in the Creator Economy
Published on 02/25/2026 at 10:05, 1 hour 5 minutes ago

Trip.com Group named ITB Innovator 2026 and returns to ITB Berlin as Official Ticket Sponsor

Les Echos

Published on 02/25/2026 at 08:55, 2 hours 15 minutes ago

Edenred takes note of the decision of the Federal Regional court on the meal and food voucher system in Brazil
Published on 02/25/2026 at 08:55, 2 hours 15 minutes ago

Edenred prend acte de la décision du président du tribunal fédéral concernant le dispositif des titres- restaurant et titres-alimentation au Brésil
Published on 02/25/2026 at 08:45, 2 hours 25 minutes ago

Air Liquide has successfully issued a CHF 640 million multi-tranche bond
Published on 02/25/2026 at 08:45, 2 hours 25 minutes ago

Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 640 millions de CHF
Published on 02/25/2026 at 07:00, 4 hours 10 minutes ago

Résultats 2025. Une performance solide dans un contexte perturbé. Marge opérationnelle : 19.5% - Marge nette : 14.1 % - Dividende par action : 1.05€

View all LES ECHOS COMFI WIRE